Undecided at this time
Conditions
Interventions
Participants will be administered one dose of ABBV-547 or placebo.
Sponsors
Otani Tetsuya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). - Part 2: must have discontinued use of phototherapy (e.g., UVA or UVB) at least 2 weeks prior to the baseline visit (Day 1) and PUVA phototherapy at least 4 weeks prior to the baseline visit (Day 1).
Exclusion criteria
Exclusion criteria: - History of any clinically significant sensitivity or allergy to any medication or food. - Part 2: uses any herbal supplements within the 2-week period prior to study treatment administration. - Part 2: received any biologics including investigational agents within 2.5 half-lives prior to Baseline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with Adverse Events (AEs) [Time Frame: Up to Approximately Day 365] | — |
Countries
Japan, United States
Contacts
Public Contactand HCP Contact for Patients
AbbVie. G.K.
Outcome results
None listed